Professor Zhu Xiuxuan, Jiahui International Hospital: The success of IMbrave150 opens a "skylight" for the immunotherapy of liver cancer

!---- recently published in the New England Journal of Medicine (NEJM), the results of the IMbrave150 study show that the combined immune treatment can be successful in liver cancerthe lead author of this study, Professor Andrew XZhu of Harvard Medical School, director of the Oncology Center at Jiahui International Hospital in Shanghai, was invited to conduct in-depth exchanges and discussions with the correspondent of the Translational Medicine NetworkProfessorZhu said the immunotherapy for liver cancer has entered a breakthrough stage, in which the IMbrave150 study is particularly important for the treatment of liver cancer and is expected to change the first-line treatment strategy for liver cancer patientsin addition, he is very much looking forward to the cooperation between Jiahui International Hospital Cancer Center and Lead Medical, and believes that with the help of the star-studded tumor precision medical platform, we can give full play to the respective advantages of the two institutionsIn introducing the research ideas, ProfessorZhu constantly mentioned the survival and quality of life of liver cancer patients, and effectively started from the clinical, for the sake of patients, so that the small editor admiresAsk 1, Professor Zhu Hello, thank you for taking the time to accept this interview in your busy scheduleAs an internationally recognized expert in the field of liver cell and bile duct cancer, can you briefly describe the common methods of liver cancer treatment? Which is the best? The treatment of liver cancer is actually very comprehensive, because we do have a lot of treatment options, including some cures - surgical excision, liver transplantation and ablationsome of these treatments are completely needles for non-removable tumors that are confined to the liver, so we can control the disease in the liver by means such as intervention and radiotherapythere is also a systematic treatment, or drug therapyit used to be limited to chemotherapy drugs, but over the years we've started to convert to targeted drugs, and now we're converting to immunotherapyrecent developments, targeting and immunotherapy have begun to be combined, as liver cancer has recently been very successfulimmunotherapy is actually a very meaningful application for the treatment of liver cancerwe know that there are many immune microenvironment changes in the process of liver cancer, all kinds of liver cancer causes, whether it is viral hepatitis (hepatitis, C), or other alcoholic hepatitis, fatty hepatitis, there are very strong chronic inflammatory changesin this process, inflammation can affect the microenvironment of the tumor, form immunosuppression, indirectly leading to liver cancerin recent years, there have been some good drug attempts to treat themleading treatment, is a drug such as checkpoint PD1/PD-L1 antibodythrough the application of such immunocheckpoint inhibitors, we have evidence that some liver cancer patients benefit from this, on this basis can further explore which drugs or other local treatment methods, and single-drug immunocheckpoint inhibitors can be combined with the application to improve efficacyAsk 2, in recent years, immunotherapy in the field of cancer is in full swing, do you think the immuno-anti-vascular combination therapy will be very promising? A Immunotherapy and antivascular therapy are a very meaningful combination of treatmentsit is a consensus that we have come to the consensus through our exploration of the mechanism of liver cancer: the angiogenesis process itself is an important cause of liver cancerdue to the enhancement of vascular production, but also increased the transformation of the immune microenvironment of liver cancer, that is, angiogenesis can lead to the formation of the immune suppressive environmentimmunosuppressive microenvironment is actually reversible, one way is to apply it in combination with antiangiogenesis inhibitors and PD1 antibodiesin this process, due to the application of antiangiogenesis inhibitors, whether specific VEGF antibodies, or small molecule multi-target inhibitors that inhibit VEGFR2, the immune microenvironment can be reversed, making it from immunosuppression to an immunoactive environmentincreased anti-tumor efficacy through joint application with PD1/PD-L1 antibodiesAsk Ed3, may, in May this year, the New England Journal of Medicine published the complete study data of the Phase III clinical trial IMbrave150 study, giving us hope for a first-line treatment for liver canceryou, as the lead author of the study, what is the special significance of the code "IMbrave150"? Where is the breakthrough point of this study? Under what circumstances did you decide to conduct this study with other experts? A This study is of great significance in the treatment of liver cancerfor nearly a decade, standard first-line treatments rely only on small molecule-targeted drugs, TKI, and the real standard is that we have dominated the small molecule drug sorafenib for more than 12 yearswe have worked a lot, just successfully developed another multi-target drug, runivalitinbut Theronatini has not proved to be superior to Soraphini, except that Theronvatini is no less than Soraphini compared to his survival periodour first combination of treatment, proving that combined beva monoabandagain and atilizumab are definitely superior to sorafenis, beva sing-it-and-a-bead-singy-singy combinations are superior to sorafeni in several other very important aspects first, it is relatively longer than the total survival; second, it is also prolonged for progression-free survival; third, it is an increase in tumor remission rate; fourth, from a safety point of view, completely exceeds our expectations, the combination of two drugs is actually compared with the single drug solafenine, its safety is very satisfactory, there are no more serious side effects; and, most importantly, the results of the two drugs combined to assess the quality of life of patients that patients not only increase their survival, but also improve their quality of life during the drug use, which I think is a more meaningful breakthrough in this study this study is based solely on an exploration of the mechanisms of the two drugs' union, and we believe that the combination of the two drugs can indeed produce very important synergies use beva-synvirus, which reverses the immune suppression environment, and enables PD-L1 antibodies to play a better role in their processes second, both drugs have single-drug anti-liver cancer activity third, we have also conducted early clinical trials of joint applications of two drugs we get very good tips in Phase I clinical trials that the two drugs are much higher than we would expect from single drugs in terms of anti-tumor remission rates because of these very important findings, we think this is a good option to develop Phase III clinical trials Question 4, the success of the IMbrave150 trial, for the liver cancer treatment history opened a new page What do you think the future of liver cancer treatment will look like? A 2020 is a very important time for liver cancer first, and has now led to the development of many different drugs in liver cancer new breakthroughs in combined treatment options, and a variety of joint programmes are being further tried in the treatment of liver cancer a joint approach here, including the idea we just talked about, specifically an antiangiogenic inhibitor and immunoogenic inhibitors we also have an exploration of immunotherapy options combined with checkpoint inhibitors and another checkpoint inhibitor, new immunoassay inhibitors, and whether cell immunotherapy, such as CAR T cells, will be effective in advanced liver cancer as we explore drug research on the treatment of advanced liver cancer, we are also exploring some more meaningful questions: whether we can move this very effective treatment of advanced stage cancer to early liver cancer treatment, such as after the surgical removal of liver cancer, we can improve the chances of long-term survival after surgery, reduce the chances of recurrence after surgery in-depth research on more complementary therapies is also under way, and the development of this very instructive combination of early and late stage joint large-area clinical studies, such as the combination of drugs, interventional therapy and other local therapies, will certainly bring a new pattern to future clinical treatment this pattern could be a major breakthrough in the quality of life and extended survival of liver cancer patients , we're at an updated time, and we want to be able to try to explore why some liver cancer patients are more sensitive to a particular option translational medicine gives us new hints about whether there are some molecular marker genetic testing characteristics that can guide us to predict whether one option is superior to other options that will benefit patients more, which is a very welcome direction Ask 5, recently, I heard that Star Medical officially signed a strategic cooperation agreement with Shanghai Jiahui International Hospital Cancer Center, you have played an important role in this cooperation, as well as the activities and meetings organized by the star, you see what role this cooperation will play in the future treatment of liver cancer? What are the plans for the future? A lead-in-the-art medicine is a very important leader in the field of molecular detection in China The cooperation between Jiahui International Cancer Center and Star Medicine is of great significance in the future, we will be able to use the testing platform of the Lead Star CLIA/CAP International Certification Standard, molecularly label liver cancer patients and conduct very systematic research on some of the characteristic genotypes that drive tumor growth, and guide our next clinical trial design to accurately develop targeted treatment options for some patients with specific molecular markers this cooperation increases our chances of success in this regard , star medicine can also provide more direct guidance to many patients' choices of treatment options, so that patients get the most benefit, so I hope this partnership can bring a lot of success Professor Zhu Xiuxuan, Professor , Dr Zhu Xiuxuan, Director of the Oncology Center of Shanghai Jiahui International Hospital, is currently a Professor at Harvard Medical School, a Fellow of the American College of Physicians (ACP), ADP, Director of the Oncology Center of Shanghai Jiahui International Hospital, and a former Director of the Liver Cancer Research Center at Massachusetts General Hospital Professor Zhu is an international lying expert in the field of hepatocellular and bile duct cancer, and has been the project leader in a number of major international clinical trials of liver, bile duct and other gastrointestinal cancers Dr Zhu Xiuxuan graduated from Peking University's Department of Medicine with a degree in clinical medicine, and then went to the United States to study for a ph.D from Columbia University he completed inpatient training and oncology specialist training at Yale-New Haven Hospital and Memorial Sloan-Kettering Cancer Center Before joining the club , he was director of the Liver Cancer Research Center at Massachusetts General Hospital Professor Zhu Xiuxuan is a founding member of the International Liver Cancer Association (ILCA), a fellow of the American College of Physicians (ACP), and a member of the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR) Professor Zhu Xiuxuan led the establishment of a multidisciplinary liver cancer center at Massachusetts General Hospital in 2009, establishing a weekly multidisciplinary liver and bile cancer clinic with oncology surgery, transplant surgery, interventional radiology, radiation oncology, hepatology and pathology , during his time as Director of the Center for Liver Cancer Research at Massachusetts General Hospital, he led a series of clinical studies in advanced hepatocellular carcinoma (HCC) and bile duct cancer (BTC), including a major ground-breaking clinical study approved by the U.S Food and Drug Administration (FDA) for pabolizumab and remoresssonite in advanced liver cancer adaptation, and the successful development of a new therapeutic target inhibitor (Ivoniside) in biliary cancer , led by Professor Zhu Xiuxuan, and by 2019, his team has established the largest hepatocellular cancer treatment center in New England, USA, which is now one of the most active platforms for clinical research on liver cancer in the United States Source: Conversion Medicine Network !-- Content Presentation Ends -- !-- Determine signed-off